SUBSCRIBE
SUBSCRIBE

Cabaletta Bio

IN THE PRESS
Press Releases
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
September 26, 2024
 · 
3 min read
Press Releases
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
August 28, 2024
 · 
2 min read
Business
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 8, 2024
 · 
16 min read
Pharm Country
Cabaletta Bio to Participate in the 2024 Jefferies Global Healthcare Conference
May 29, 2024
 · 
1 min read
Business
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024
 · 
14 min read
Pharm Country
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024
 · 
1 min read
Business
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024
 · 
14 min read
Pharm Country
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
March 20, 2024
 · 
8 min read
Pharm Country
Cabaletta Bio to Participate in Upcoming Investor Conferences in March 2024
February 27, 2024
 · 
1 min read
Pharm Country
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
February 1, 2024
 · 
8 min read
Load More
JOBS